Dyne Therapeutics, Inc.
corporate_fare Company Profile
Dyne Therapeutics, Inc. (NASDAQ:DYN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 44 items for DYN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for DYN spans 10-Q, 8-K, 4, 144.
Recent high-impact activity:
- Dyne Q3 Loss Widens to $193.6M; Cash of $1.13B Funds Runway Into Q2 2028
- Z-Basivarsen Delivers Durable One-Year Functional Gains in DM1, Separating From Natural History
- Dyne's DYNE-101 Shows 12-Month Functional Gains in DM1; REC Topline Set for Q1 2027
- Director Jason Rhodes Sells $65.2M in Dyne Stock via 10b5-1 Plan
- Atlas Venture intends to sell $8.37M in Dyne stock, continuing recent distribution
Financial Snapshot
Short Interest & Short Volume
10.81 days to coverFINRA reported short interest of 24,376,615 shares in DYN as of the October 30, 2026 settlement, a 4.3% decrease from the prior period — about 10.8 days to cover at its recent average daily volume. On November 20, 2026, 33.1% of DYN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for DYN, detected from its recent SEC filings · based on capital-structure filings through 2026-07-22.
Upsized Offering Priced at Discount · Dilution Impact
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →